Zoetis Inc. (NYSE:ZTS) Shares Sold by Bath Savings Trust Co

Bath Savings Trust Co decreased its stake in Zoetis Inc. (NYSE:ZTS) by 4.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,682 shares of the company’s stock after selling 1,081 shares during the period. Bath Savings Trust Co’s holdings in Zoetis were worth $4,432,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Price T Rowe Associates Inc. MD increased its stake in Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Sarasin & Partners LLP increased its position in shares of Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after buying an additional 1,904,899 shares in the last quarter. Swedbank AB purchased a new position in shares of Zoetis in the first quarter valued at $210,815,000. Marshall Wace LLP boosted its position in shares of Zoetis by 7,608.6% in the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after buying an additional 824,843 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Zoetis by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 40,334,966 shares of the company’s stock valued at $7,960,912,000 after acquiring an additional 536,477 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on ZTS shares. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler boosted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Stifel Nicolaus increased their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus price target of $220.38.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $187.28 on Tuesday. The business has a fifty day simple moving average of $187.30 and a 200-day simple moving average of $175.50. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a market cap of $84.85 billion, a P/E ratio of 36.08, a P/E/G ratio of 2.91 and a beta of 0.89. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.41 EPS. Equities research analysts forecast that Zoetis Inc. will post 5.84 EPS for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.